Physician profile
David Mock
NPI 1063458032
$4,861.85
in general payments reported to CMS, 2019-2025
22 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $1,542 · 2021: $926 · 2022: $129 · 2023: $472 · 2024: $194 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.38 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,164.35 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,063.28 | 2019-2023 | Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $408.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.69 | 2019-2023 | Ofev |
| Regeneron Healthcare Solutions, INC. | $261.25 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $231.83 | 2019-2021 | |
| Grifols USA, LLC | $224.20 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Mylan Specialty L.P. | $158.44 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $139.19 | 2019-2024 | Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $127.36 | 2019 | |
| Pfizer INC. | $110.92 | 2019-2021 | |
| Genzyme Corporation | $100.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.50 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.80 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.45 | 2019-2020 | |
| Insmed, INC. | $45.01 | 2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $31.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2020 | |
| Viatris Specialty LLC | $14.30 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $14.22 | 2021 | |
| Shire North American Group INC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.